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Prostate cancer remains a significant health problem worldwide and is the second highest cause of cancer-related death in men.
While there is uncertainty over which men will benefit from radical treatment, considerable efforts are being made to reduce
treatment related side-effects and in optimising outcomes. This article reviews the development and introduction of robotic-assisted
laparoscopic radical prostatectomy (RALP), the results to date, and the possible future directions of RALP.
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Prostate cancer remains a significant health problem worldwide
and is the most common cancer affecting men in the United
Kingdom, with over 34000 cases diagnosed in 2005. It is the
second leading cause of cancer-related death among men in the UK
and the lifetime risk of being diagnosed with prostate cancer is
around one in ten. In contrast, in the United States, it is the third
commonest cause of cancer-related death among men and the
lifetime risk of being diagnosed is one in six, which largely is the
consequence of higher rates of PSA testing and screening.
Conventional treatment options include radical prostatectomy
(RP), external beam radical radiotherapy, brachytherapy and
active monitoring or surveillance with or without regular biopsy.
More recently, focal therapies such as cryoablation and high-
intensity focused ultrasound have been introduced, but their
oncological effectiveness remains uncertain. Radical prostatectomy
is an established and accepted treatment for localised and more
recently, for locally advanced prostate cancer. Overall 10-year PSA
progression rates after RP are around 30%. Recurrence rates are
increased in men with a higher pre-operative PSA, Gleason grade,
or tumour stage and if there are positive margins in the
pathological specimen.
Surgery can be performed by traditional open surgery, or
laparoscopically – with or without robotic assistance. This article
reviews the development and introduction of robotic-assisted
laparoscopic RP (RALP), the results to date, and the possible
future directions. In order to concentrate on outcomes when the
learning curve has been passed, we have for the purposes of this
review included studies where 500 or more cases of RALP have
been reported plus other selected references.
HISTORY OF RADICAL PROSTATECTOMY
The first perineal prostatectomy was performed by Proust in
France in 1901, followed by Young in 1905 in the United States of
America who performed the surgery on men with prostate cancer.
During the early years, there was significant mortality and
morbidity, with some surgeons reporting up to 30% mortality
rates. Improvements in technique were made, and Millin’s
retropubic prostatectomy was used for patients with prostate
cancer by Memmelaar and others from the late 1940’s. It was not
until 1983 that the operation was refined by Walsh who also
reported the use of a nerve-sparing procedure to improve post-
prostatectomy potency rates. The first laparoscopic RP was
performed in 1991 by Schuessler and, as with open surgery,
advances have been made to improve outcomes, including
development of new technologies.
Despite this, there remains significant morbidity associated
with RP, most notably urinary incontinence and erectile
dysfunction. In general the results from referral centres are better
than outcomes derived from national databases, most likely
to be related to different outcomes in high- and low-volume
centres. The Prostate Cancer Outcomes Study (part of the
Surveillance, Epidemiology and End Results (SEER) program),
which reports results from a wider variety of centres, many of them
low-volume, showed post-RP continence and potency rates of 48
and 20%, respectively, at 2 years (Potosky et al, 2000), whereas
single-centre series (as shown in Table 1) show continence and
potency rates of around 76–97% and 46–87% at a similar length
of follow-up.
The difficulties in comparing such outcomes arise from the
different methods of recording and reporting complications, the
different lengths of follow-up, and varying definitions. When it
comes to proxy oncological outcomes there is also the factor of
looking at different types of disease because we know that
significant stage migration occurs upon community-based screen-
ing programmes (Moore et al, 2009).
DEVELOPMENT OF THE da Vinci ROBOTIC SYSTEM
A program was established in the late 1980’s in the US to develop a
system capable of performing remote surgery for use in warzones.
Intuitive Surgical realised the commercial potential, and the da
Vinci surgical system was launched in 1999. It received FDA
approval for general laparoscopic surgery in 2000. The system
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the operation and the robot itself with three (or four) operating
arms connected to various surgical instruments. The key beneficial
features include up to 12 times magnification, three-dimensional
vision, and seven degrees freedom of movement with the
instruments.
The first RALP was performed in Frankfurt in May 2000
and the first in the UK was performed at St Mary’s
Hospital, London, in November 2004. Within the UK, there are
currently 14 centres using a da Vinci robotic system for urological
surgery.
The system itself costs around d1.5 million to install. Even not
taking account of capital depreciation and the cost of the robot,
each RP carries a real excess cost of around d1300 owing to the use
of disposable instruments. The number of hospitals carrying out
RALP worldwide is steadily increasing. In the US RALP accounts
for 70% of all RP cases. In Europe, this figure is significantly lower,
at 14%, but rising.
METHODS OF PERFORMING ROBOTIC RP
The Vattikuti Institute Prostatectomy (VIP) was first described by
Menon et al (2003) and incorporated principles taken from
laparoscopic and open techniques, reflecting the input of European
Urologists to its development (Pasticier et al, 2001). The main
principles of the VIP include development of the extraperitoneal
space, lymph node dissection if indicated clinically (i.e. for
intermediate- and high-risk cases), incision of the endopelvic
fascia, dorsal vein complex control, bladder neck transection,
posterior dissection, control of the lateral pedicles, release of the
neurovascular bundles, retrograde apical dissection, division of the
dorsal venous complex and urethra, vesico-urethral anastomosis,
specimen retrieval, and completion.
As with other forms of RP, nerve-sparing procedures should
only be performed when the surgeon is confident of achieving
good cancer control. Nerve sparing can be either unilateral or
bilateral, depending on stage, grade and volume of disease, and
pre-operative erectile function. A number of guidelines have been
reported to guide the surgeon as to the likely safety of nerve
sparing, including the Partin Tables from Johns Hopkins, the
Kattan Nomogran from Memorial Sloan Kettering, and the ‘New
York University nerve sparing algorithm’, which takes account of
the Gleason score, perineural invasion, and tumour volume
in the biopsy specimen (Partin et al, 1993; Kattan et al, 1997;
Shah et al, 2003).
SURGICAL MODIFICATIONS
Since the initial introduction of RALP, various groups have
reported modifications to the original VIP technique. The Van
Velthoven anastomosis, consisting of a running suture, was
reported for both laparoscopic and robotic prostatectomy in
2003 (Van Velthoven et al, 2003), and is now a standard technique
used in RALP. Kaul et al (2005) first reported the preservation of
the high lateral prostatic fascia, in addition to the traditional
‘neurovascular bundle preservation’, which led to improved
potency rates, probably because it reduces intra-operative tension
on the bundles. However, it risks higher positive margin rates
(PMRs) and should be reserved for patients with very-low-risk
disease. The avoidance of thermal injury of the neurovascular
bundle is general good surgical practice and has been highlighted
by many authors, including Ahlering et al (2006), with short-term
results showing a difference in potency rates between cautery and
non-cautery techniques.
The Rocco suture was first described in radical retropubic
prostatectomy by Rocco in 2007 (Rocco et al, 2007) and has been
reported by Tewari et al (2008) for its use in RALP. This is a
posterior reconstruction to support the urethral sphincter, and it
has been used in combination with the Pagano suture, which adds
further reinforcement to the posterior bladder neck. Tewari et al
reported an earlier return to total urinary continence using this
with 83% of patients being continent at 6 weeks. However, there
has been no randomised controlled trial to support the use of
either the Rocco or the Pagano suture, and the benefits which have
been shown by them could also represent learning-curve effects.
More recently the use of extended pelvic lymph node dissection
has been demonstrated in RALP and was shown to be feasible with
respect to both surgical technique and number of lymph nodes
removed (Feicke et al, 2009). The indications and clinical benefit of
this in open, laparoscopic, or robotic-assisted approaches remain
unclear, although an increased number of positive nodes are found
when this is carried out (Dhar et al, 2007).
As more surgeons undergo RALP, it is likely that further
modifications will be made, aimed at improving functional
outcomes. It is important to recognise that oncological outcomes
must be perfected and that the primary aim of any radical
procedure for prostate cancer is cancer control.
THE LEARNING CURVE
Learning curves have been reported for open, laparoscopic, and
robotic-assisted laparoscopic prostatectomy. A recent review of
Table 1 Comparison of outcomes of different types of radical prostatectomy
Patient Overall
PMR by pathological stage (%)
EBL Mean operative Follow-up Continency Potency Biochemical
Series number PMR (%) T2 T3a T3b T4 (ml) time (min) (months) % % recurrence
a
Laparoscopic:
Lein et al (2006) 1000 26.5 15 53 60 100 200 266 29 76 — 9.5
Touijer et al (2009) 1564 13.0 — — — — — — 96 — — 29
Eden et al (2009) 1000 13.3 — — — — 200 177 28 95 66 3.9
RALP
Badani et al (2007) 2766 — 13 35
b 35
b — 142 154 22 93 79 7.3
Patel et al (2008) 1500 9.3 4 34
b 34
b 40 111 105 — — — —
Tewari et al (2008) 700 — — — — — — — 12 97 87 —
Authors’ institute
c 440 23 16 30 51 100 200 180 12 94 75 —
Abbreviations: EBL¼Estimated Blood Loss; PMR¼positive margin rate; RALP¼robotic-assisted laparoscopic radical prostatectomy.
aBiochemical relapse rate (usually at PSA
40.2ng/ml) is reported at various times after surgery making direct comparisons difficult.
bPMR for all pT3 specimens.
cSee separate note on recent data from one surgeon.
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reducing cancer risk continued up to 750 cases, which suggests
that the learning curve for LRP is greater than that for open RP
(Vickers et al, 2009). There are no randomised data, but one real
benefit of RALP would be a reduction in the oncological learning
curve, compared with LRP. Case report series suggest that this is
the case, but there is variation in how learning curves are reported,
although most include operating time, blood loss, and rates of
positive margins. The learning curve of RALP is associated with
the use of innovative technology, loss of tactile (haptic) feedback,
and an entirely novel surgical view. It has been suggested that there
are two learning curves in RALP – first, to perform the operation
safely and with clear margins, and second, to perform nerve-
sparing procedures. Menon et al (2002), Ahlering et al (2003), and
Artibani et al (2008) reported that the learning curve with RALP
for experienced open surgeons is at least 20 cases, simply to
perform the operation safely. Ahlering et al (2003) and Menon et al
(2003) also showed that surgeons with previous experience of open
prostatectomy have similar complication rates after 20 cases of
RALP, compared with a laparoscopic surgeon after 100 cases of
laparoscopic RP, suggesting that the learning curve for RALP is
shorter than that for laparoscopic RP, at least with regard to
complications. There is a suggestion that previous experience of
laparoscopy might actually result in a longer learning curve for
RALP than for those with open experience (Zorn et al, 2007). Other
studies have shown much longer learning curves for RALP, with up
to 200 cases (Mikhail et al, 2006).
While uncertainty surrounds the duration of the learning curves
for RALP, it is critical that centres embarking on starting a
program do so with supervision and structured support. Close
mentoring by an experienced team is beneficial when starting to
perform RALP: Kaul et al (2006) reported a two-person mentoring
team (with experience of over 1000 RALPs) training the console
surgeon and the assistant for five cases, after the entire surgical
team had undergone 1 week of intensive training. This was
followed by a period of mentoring by an experienced laparoscopic
surgeon for a further 40 cases. This approach has led to
satisfactory outcomes and such approaches should be used by
centres implementing RALP. The optimal duration of this
mentoring period is not clear; Dr Menon was proctored for the
first 100 cases that he performed. A structured approach when
starting this technique should include mentoring by experienced
RALP surgeons for as long as is necessary to pass through the
‘learning curve’, in order to offer patients the best possible
oncological and functional outcomes. However, a standardised
program for the implementation of RALP has not yet been
developed. There has been concern that initial outcomes have not
been as good as they should have been because of inadequate
mentoring. Ideally large-volume centres would provide a ‘mentor-
ing team’ for new RALP centres, with an appropriately targeted
mentoring period depending on the surgeon’s competence.
RESULTS OF DIFFERENT TYPES OF RP
There are no randomised controlled trial data on the outcomes of
robotic-assisted vs laparoscopic vs open RP. Until such a study has
been performed, the best observations come from reviews, which
have compared outcomes from all three surgical options. Table 1
shows outcomes from large series of laparoscopic and robotic-
assisted surgery.
In our institute, more than 440 men have now undergone RALP,
with a mean age of 62 years and an average operating time of
180min. We have a stringent system of pathological reporting with
step-sectioning of whole mounted specimens. As with other series,
the PMR correlated with pathological stage, with 16% in pT2 and
36% in pT3. Two patients had pT4 disease and both had positive
margins. While these stage-specific PMRs for T2 disease are
somewhat higher than those from contemporary open and
laparoscopic series, this is, in part, likely to represent a difference
in disease burden rather than a difference solely due to surgical
technique. For instance, 42% of our patients had pT3 disease,
indicating a population with higher stage disease than in other
centres, particularly those with screened patient populations.
When these results are compared to open series from the US
before PSA screening took place, the PMRs are much more
comparable (around 30% overall, with higher rates for pT3 and
pT4 disease; Wieder and Soloway, 1998). More recent comparisons
of European countries, where PSA testing is common, with the US
have shown that the overall pathological stages are similar (Gallina
et al, 2008), suggesting that the UK results are related to a low
baseline level of PSA testing (Moore et al, 2009). However, we
recognise that our PMR for patients with pT2 disease needs to be
improved, and this is likely to be achieved by improving our
patient selection for nerve-sparing procedures. With regards to
functional outcomes from our institute, 75% of men are
sufficiently potent for intercourse at 12 months, with 25% of these
men using no adjuvant treatment. For patients in whom the Rocco
stitch was used (the last 200 patients), 80% of men are fully
continent at just 6 weeks. At 10 months, 94% are completely
continent.
In a recent separate analysis of a single surgeon’s learning curve
from our institute, we noted continued improvement in surgical
outcomes for the last 70 cases: the overall PMR for these later cases
is 19% and stage-specific rates are 10, 23, and 100% for pT2, pT3,
and pT4 respectively. Median operating time is reduced at 2h
10min and median blood loss is 150ml. These data are comparable
with evidence from open surgeons that volume and outcome are
related, in other words high-volume surgeons have lower positive
margin rates (Chun et al, 2006; Wilt et al, 2008).
With respect to blood loss, it appears that RALP is superior to
open and laparoscopic RP (Frota et al, 2008). While early results
are promising, some studies have reported higher complication
rates with RALP compared with open RP: Hu et al (2008) showed
an anastomotic stricture rate of 15.2% in the RALP group,
compared with 12% in the open group. However, only 608 patients
had RALP, compared with 2094 patients who had open RP, and
this was not a single-surgeon analysis. These rates of anastomotic
strictures have not been found in most studies, and have not been
found in the authors’ series.
Despite there being many published studies, there are few and
limited comparative data available, due to the differences in
outcome measures recorded by different groups, as has been
recently highlighted by a review of the surgical options for prostate
cancer (Ficarra et al, 2009). In order to fully counsel a patient
about which surgical modality to choose with regards to
complications, and oncological and functional outcomes, a large
randomised controlled trial comparing open vs laparoscopic vs
robotic-assisted prostatectomy is required. However, in the
meantime centres should provide patients with their own local
outcome data.
There are common predictors of recurrence after all forms of
RP, and these include high pre-operative PSA, high Gleason grade,
high pathological stage, and positive surgical margins. All the
series shown in Table 1 highlight the low PMR associated with low-
stage disease, that is pT2, but higher rates with higher stage
disease. We should aim to reduce the PMRs associated with both
pT2 and pT3 disease.
The stage and grade of prostate cancer in different countries
varies significantly depending on the underlying rate of prostate
cancer screening. It is clear that widespread community-based PSA
testing results in ‘stage migration’ where most of the cancers are
detected at T1 or T2 disease of Gleason grade 6, with low volumes
of cancer on biopsy (Postma et al, 2006; Collin et al, 2008; Moore
et al, 2009). Such men will have low rates of positive margins. In
the UK, the underlying rate of PSA testing is low, and many more
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even in the D’Amico low risk category will tend to have higher
volumes of cancer – this needs to be borne in mind when
comparing UK figures with those from the US and Europe where
screening is more common.
Variations in pathology reporting can also affect the PMR due to
differences in specimen sampling. Desai et al (2002) reported
higher rates of detection of extra-prostatic extension in specimens,
which underwent complete embedding and close step-sectioning,
compared with partial sampling. Clearly this has implications for
higher detection rates of positive margins, and the method used by
each centre should be considered when interpreting PMRs.
Rigorous and standardised follow-up data collection is crucial to
allow adequate comparison between reported series and assess
individual performance. While oncological and functional out-
comes are routinely evaluated, quality of life (QoL) is often
overlooked. Namiki et al (2009) have studied the effect of open RP
on QoL using the Short Form 36-Item Health Survey (SF-36) and
other prostate-specific questionnaires, and showed that by 5 years
most men had returned to baseline levels of QoL. White et al
(2008) compared QoL outcomes for patients from the CapSURE
database with locally advanced prostate cancer undergoing
different treatments, and showed that all treatments were
associated with reductions in QoL scores, although they were
unable to determine the ‘best’ treatment with regards to QoL.
The results of the ProtecT Study will address some of these QoL
issues relating to different treatment options (Donovan et al, 2002;
Wilt, 2008), but larger studies of RALP are required to show
whether there is any benefit on QoL as compared with other
treatments. If functional outcomes improve earlier after RALP, it
may be that patients would return to a baseline QoL sooner
following RALP as compared with other treatments.
A recent study by Schroeck et al (2008) showed that patients
who had RALP were 3–4 times more likely to be dissatisfied and
regretful than patients who had undergone open RP. The authors
proposed that this was likely due to the higher level of expectations
by the RALP patients, which highlights the importance of
providing patients with accurate, ‘neutral’, and realistic informa-
tion regarding post-operative recovery and function. Indeed, this
approach has resulted in 91% of RALP patients expressing no
dissatisfaction or regrets in the series from the Vattikuti Institute
(Menon and Bhandari, 2008). We believe that careful presentation
of outcome information and data, coupled with a more neutral
approach with respect to discussion of radical vs conservative
approaches, will result in lower rates of dissatisfaction. This is of
particular relevance when introducing RALP, and when a single
centre has performed far fewer than 500 cases. In order for
informed consent to be obtained, a frank and thorough discussion
must take place, highlighting the likely outcomes for the patient
based on the surgeon’s own data, rather than the frequently quoted
large studies in the literature with favourable outcomes.
FUTURE DIRECTIONS
As improvements in operative techniques continue to improve
rates of continence and potency, the robotic system is likely to gain
in popularity. In addition, the system itself continues to be
updated, with the latest ‘Si system’, including high-definition
screens. The loss of tactile feedback remains an issue and novel
engineering approaches are being tested to try to resolve this issue.
Also there will be a need for continued modifications of the
instruments to try to increase their delicacy, such as the need to
decrease the size of the bipolar instrument. Due to the significant
costs, however, it is likely to remain a system used only by larger
centres, and it should be mandatory that continuous review of the
outcomes is undertaken by each department. This should be
standardised in order to allow comparisons between centres and
included in this must be detailed assessment of continence and
potency rates (pre- and post-operatively), and complications.
These standards should be used by all surgeons performing RP and
this will enable a large, prospective, multicentre randomised trial
to be performed comparing robotic-assisted, open, and laparo-
scopic RP. Surgeons will be required to show the benefits of RALP
for their own centre, and each surgeon’s outcomes must be
assessed. It is not appropriate for centres to quote rates of other
institutions, which may be far more favourable than their own.
The robotic system has recently been used in conjunction with
laparo-endoscopic single-site surgery to perform RP in several
institutions (Barret et al, 2009; Kaouk et al, 2009). This was
performed via a single umbilical incision, with all instruments
used through the single site. This illustrates the shift in surgery
over recent years to provide a procedure with optimal oncological
and functional outcomes, with a cosmetic result comparable to that
of minor surgery.
It is clear that surgery must be applied to those patients most
likely to benefit. Some men with low-risk prostate cancer will not
benefit from radical treatment of any sort, but identification of
them remains problematic. The approach of active surveillance or
active monitoring, where men are followed up carefully with
regular PSA testing, is one approach, but not as yet proven to
safely identify men at risk of future prostate cancer morbidity
(D’Amico et al, 2005, 2006). It is likely that a combination of
personal genetic information (Eeles et al, 2008) coupled with
measurement of several biomarkers in serum, urine, and most
importantly in prostate biopsy tissue, will be able to identify men
at high or low risk of progression, which will focus targeting
radical treatment to the right group.
Traditionally surgery has not been widely used for intermediate-
and high-risk prostate cancer, but results have shown reasonable
long-term cancer control rates (Ward et al, 2005; Hsu et al, 2007).
Indeed there is a growing realisation that surgery should be
targeted at these men, although higher rates of positive margins
requiring post-operative radiotherapy will be found. Should we be
aiming RALP at those requiring management of locally advanced
disease where oncological outcomes remain poor but could be
significantly improved? Lessons from the management of breast
cancer can be learnt, with programmes of multi-modal treatment
offered to high-risk cancers. Currently, RALP is used most for
patients with low-risk localised disease. It is already widely
published that PMRs increase with tumour stage and that positive
margins are an independent risk factor for recurrence. If PMR can
be reduced by an enhanced surgical technique, then progression-
free rates might be improved for a subset of patients with higher
risk localised disease. Currently, progression-free rates at 10 years
are 37% for patients with pT3b disease, 76% for pT3a disease, and
93% for pT1/T2 disease (Han et al, 2001). Given the benefits of
robotic surgery, it seems logical to propose that the operation
could be optimised for patients with locally advanced disease, and
give outcomes which are more favourable than those currently
achieved.
CONCLUSION
The lack of randomised trials in this new technology makes
assessment difficult. However, there is clear evidence from
retrospective studies that robotic-assisted laparoscopic prostatect-
omy can achieve excellent oncological and functional outcomes.
Centres which are embarking on this procedure must be aware of
its associated learning curve and should adopt a carefully
structured mentoring approach to minimise this. Follow-up data
should be comprehensive and standardised, and include QoL
scores, which will enable results of future randomised controlled
trials to be useful in clinical practice. The future of robotic surgery
for prostate cancer is exciting and there are likely to be many
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locally advanced disease. With the increasing use of RALP, it is
important for surgeons to counsel patients and provide realistic
expectations of the outcomes, including the likelihood of multi-
modal treatment, when locally advanced disease is present.
Caution must be exerted when ‘developing’ technologies, and it
must always be remembered that the primary aim of radical
therapy is cancer control.
REFERENCES
Ahlering TE, Skarecky D, Borin J (2006) Impact of cautery vs cautery-free
preservation of neurovascular bundles on early return of potency.
J Endourol 20: 586–589
Ahlering TE, Skarecky D, Lee D, Clayman RV (2003) Successful transfer of
open surgical skills to a laparoscopic environment using a robotic
interface: initial experience with laparoscopic radical prostatectomy.
J Urol 170: 1738–1741
Artibani W, Fracalanza S, Cavalleri S, Iafrate M, Aragona M, Novara G,
Gardiman M, Ficarra V (2008) Learning curve and preliminary
experience with da Vinci-assisted laparoscopic radical prostatectomy.
Urol Int 80: 237–244
Badani KK, Kaul S, Menon M (2007) Evolution of robotic radical
prostatectomy: assessment after 2766 procedures. Cancer 110: 1951–1958
Barret E, Sanchez-Salas R, Kasraeian A, Benoist N, Ganatra A, Cathelineau
X, Rozet F, Galiano M, Vallancien G (2009) A Transition to
Laparoendoscopic Single-Site Surgery (LESS) radical prostatectomy:
human cadaver experimental and initial clinical experience. J Endourol
23: 135–140
Chun FK, Briganti A, Antebi E, Graefen M, Currlin E, Steuber T, Schlomm
T, Walz J, Haese A, Friedrich MG, Ahyai SA, Eichelberg C, Salomon G,
Gallina A, Erbersdobler A, Perrotte P, Heinzer H, Huland H, Karakiewicz
PI (2006) Surgical volume is related to the rate of positive surgical
margins at radical prostatectomy in European patients. BJU Int 98:
1204–1209
Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D,
Hamdy F, Stephens P, Lane JA, Moore R, Donovan J (2008) Prostate-
cancer mortality in the USA and UK in 1975–2004: an ecological study.
Lancet Oncol 9: 445–452
D’Amico AV, Chen MH, Roehl KA, Catalona WJ (2005) Identifying patients
at risk for significant vs clinically insignificant postoperative prostate-
specific antigen failure. J Clin Oncol 23: 4975–4979
D’Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ
(2006) Identifying men diagnosed with clinically localized prostate cancer
who are at high risk for death from prostate cancer. JU r o l176: S11–S15
Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C,
Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl
D, Moul JW (2002) Complete embedding and close step-sectioning of
radical prostatectomy specimens both increase detection of
extra-prostatic extension, and correlate with increased disease-free
survival by stage of prostate cancer patients. Prostate Cancer Prostatic
Dis 5: 212–218
Dhar NB, Burkhard FC, Studer UE (2007) Role of lymphadenectomy in
clinically organ-confined prostate cancer. World J Urol 25: 39–44
Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal
D, Hamdy F (2002) Quality improvement report – Improving design and
conduct of randomised trials by embedding them in qualitative research:
ProtecT (prostate testing for cancer and treatment) study. Br Med J 325:
766–769
Eden CG, Neill MG, Louie-Johnsun MW (2009) The first 1000 cases of
laparoscopic radical prostatectomy in the UK: evidence of multiple
‘learning curves’. BJU Int 103: 1224–1230
Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK,
Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI,
Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR,
Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O’Brien LT, Gehr-Swain
BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz
M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS,
Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher
C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF
(2008) Multiple newly identified loci associated with prostate cancer
susceptibility. Nat Genet 40: 316–321
Feicke A, Baumgartner M, Talimi S, Schmid DM, Seifert HH, Muntener M,
Fatzer M, Sulser T, Strebel RT (2009) Robotic-assisted laparoscopic
extended pelvic lymph node dissection for prostate cancer: surgical
technique and experience with the first 99 cases. Eur Urol 55: 876–883
Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M,
Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J,
Van Poppel H (2009) Retropubic, laparoscopic, and robot-assisted
radical prostatectomy: a systematic review and cumulative analysis of
comparative studies. Eur Urol 55: 1037–1063
Frota R, Turna B, Barros R, Gill IS (2008) Comparison of radical
prostatectomy techniques: open, laparoscopic and robotic assisted. Int
Braz J Urol 34: 259–268, discussion 268–269
Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer
G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, Shariat SF,
Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI (2008)
Comparison of stage migration patterns between Europe and the USA: an
analysis of 11350 men treated with radical prostatectomy for prostate
cancer. BJU Int 101: 1513–1518
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term
biochemical disease-free and cancer-specific survival following anatomic
radical retropubic prostatectomy. The 15-year Johns Hopkins experi-
ence. Urol Clin North Am 28: 555–565
Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H (2007) Outcome of
surgery for clinical unilateral T3a prostate cancer: a single-institution
experience. Eur Urol 51: 121–128, discussion 128–129
Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL (2008) Utilization and
outcomes of minimally invasive radical prostatectomy. J Clin Oncol 26:
2278–2284
Kaouk JH, Goel RK, Haber GP, Crouzet S, Stein RJ (2009) Robotic single-port
transumbilical surgery in humans: initial report. BJU Int 103: 366–369
Kattan MW, Stapleton AM, Wheeler TM, Scardino PT (1997) Evaluation of
a nomogram used to predict the pathologic stage of clinically localized
prostate carcinoma. Cancer 79: 528–537
Kaul S, Bhandari A, Hemal A, Savera A, Shrivastava A, Menon M (2005)
Robotic radical prostatectomy with preservation of the prostatic fascia: a
feasibility study. Urology 66: 1261–1265
Kaul SA, Peabody JO, Shah N, Neal D, Menon M (2006) Establishing a
robotic prostatectomy programme: the impact of mentoring using a
structured approach. BJU Int 97: 1143–1144
Lein M, Stibane I, Mansour R, Hege C, Roigas J, Wille A, Jung K, Kristiansen
G, Schnorr D, Loening SA, Deger S (2006) Complications, urinary
continence, and oncologic outcome of 1000 laparoscopic transperitoneal
radical prostatectomies – experience at the Charite Hospital Berlin,
Campus Mitte. Eur Urol 50: 1278–1282, discussion 1283–1284
Menon M, Bhandari M (2008) Unhappy patients: musings of two surgical
nihilists. Eur Urol 54: 723–725
Menon M, Shrivastava A, Tewari A, Sarle R, Hemal A, Peabody JO,
Vallancien G (2002) Laparoscopic and robot assisted radical prostatect-
omy: establishment of a structured program and preliminary analysis of
outcomes. J Urol 168: 945–949
Menon M, Tewari A, Peabody J (2003) Vattikuti Institute prostatectomy:
technique. J Urol 169: 2289–2292
Mikhail AA, Orvieto MA, Billatos ES, Zorn KC, Gong EM, Brendler CB,
Zagaja GP, Shalhav AL (2006) Robotic-assisted laparoscopic prostatect-
omy: first 100 patients with one year of follow-up. Urology 68: 1275–1279
Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH,
Donovan JL, Hamdy FC, Martin RM, Neal DE (2009) Population-based
prostate-specific antigen testing in the UK leads to a stage migration of
prostate cancer. BJU Int (E-pub ahead of print 22 June 2009)
Namiki S, Ishidoya S, Ito A, Kawamura S, Tochigi T, Saito S, Arai Y (2009)
Quality of life after radical prostatectomy in Japanese men: a 5-year
follow up study. Int J Urol 16: 75–81
Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC
(1993) The use of prostate specific antigen, clinical stage and Gleason
score to predict pathological stage in men with localized prostate cancer.
J Urol 150: 110–114
Pasticier G, Rietbergen JB, Guillonneau B, Fromont G, Menon M,
Vallancien G (2001) Robotically assisted laparoscopic radical prosta-
tectomy: feasibility study in men. Eur Urol 40: 70–74
Robotic-assisted laparoscopic prostatectomy
N Sharma et al
1495
British Journal of Cancer (2009) 101(9), 1491–1496 & 2009 Cancer Research UKPatel VR, Palmer KJ, Coughlin G, Samavedi S (2008) Robot-assisted
laparoscopic radical prostatectomy: perioperative outcomes of 1500
cases. J Endourol 22: 2299–2305
Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH
(2006) Tumour features in the control and screening arm of a
randomized trial of prostate cancer. Eur Urol 50: 70–75
Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS,
Eley JW, Stephenson RA, Harlan LC (2000) Health outcomes after
prostatectomy or radiotherapy for prostate cancer: results from the
Prostate Cancer Outcomes Study. J Natl Cancer Inst 92: 1582–1592
Rocco B, Gregori A, Stener S, Santoro L, Bozzola A, Galli S, Knez R, Scieri F,
Scaburri A, Gaboardi F (2007) Posterior reconstruction of the rhabdo-
sphincter allows a rapid recovery of continence after transperitoneal
videolaparoscopic radical prostatectomy. Eur Urol 51: 996–1003
Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ,
Robertson CN, Tewari AK, Moul JW (2008) Satisfaction and regret after
open retropubic or robot-assisted laparoscopic radical prostatectomy.
Eur Urol 54: 785–793
Shah O, Robbins DA, Melamed J, Lepor H (2003) The New York University
nerve sparing algorithm decreases the rate of positive surgical margins
following radical retropubic prostatectomy. J Urol 169: 2147–2152
Tewari A, Jhaveri J, Rao S, Yadav R, Bartsch G, Te A, Ioffe E, Pineda M,
Mudaliar S, Nguyen L, Libertino J, Vaughan D (2008) Total reconstruc-
tion of the vesico-urethral junction. BJU Int 101: 871–877
Touijer K, Secin FP, Cronin AM, Katz D, Bianco F, Vora K,
Reuter V, Vickers AJ, Guillonneau B (2009) Oncologic outcome after
laparoscopic radical prostatectomy: 10 years of experience. Eur Urol 55:
1014–1019
Van Velthoven RF, Ahlering TE, Peltier A, Skarecky DW, Clayman RV
(2003) Technique for laparoscopic running urethrovesical anastomosis:
the single knot method. Urology 61: 699–702
Vickers AJ, Savage CJ, Hruza M, Tuerk I, Koenig P, Martinez-Pineiro L,
Janetschek G, Guillonneau B (2009) The surgical learning curve for
laparoscopic radical prostatectomy: a retrospective cohort study. Lancet
Oncol 10: 475–480
Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H (2005) Radical
prostatectomy for clinically advanced (cT3) prostate cancer since the
advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95:
751–756
White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS (2008) Quality
of life in men with locally advanced adenocarcinoma of the prostate: an
exploratory analysis using data from the CaPSURE database. J Urol 180:
2409–2413, discussion 2414
Wieder JA, Soloway MS (1998) Incidence, etiology, location, prevention and
treatment of positive surgical margins after radical prostatectomy for
prostate cancer. J Urol 160: 299–315
Wilt TJ (2008) SPCG-4: a needed START to PIVOTal data to promote and
protect evidence-based prostate cancer care. J Natl Cancer Inst 100:
1123–1125
Wilt TJ, Shamliyan TA, Taylor BC, MacDonald R, Kane RL (2008)
Association between hospital and surgeon radical prostatectomy volume
and patient outcomes: a systematic review. J Urol 180: 820–828,
discussion 828–829
Zorn KC, Orvieto MA, Gong EM, Mikhail AA, Gofrit ON, Zagaja GP,
Shalhav AL (2007) Robotic radical prostatectomy learning curve of a
fellowship-trained laparoscopic surgeon. J Endourol 21: 441–447
Robotic-assisted laparoscopic prostatectomy
N Sharma et al
1496
British Journal of Cancer (2009) 101(9), 1491–1496 & 2009 Cancer Research UK